A recent paper, linked here, outlines the indications for screening and the reasons why. This has been a bit controversial, since gene product replacement has been supported only by clinical data on surrogate endpoints. However, the article makes a compelling case for screening based on several reasons. First, the surrogate based evidence is mounting. Second, there are multiple reasons beyond product replacement to justify screening.